Abbott already has an FDA-approved self-expanding TAVR valve, the Navitor system, on the market. The company is now evaluating the safety and effectiveness of a new balloon-expandable device that could potentially be implanted using software guidance. 

New research into post-concussion brain health suggests that the impact of head trauma may be more far-reaching than previously believed. 

The pressure changes associated with contrast injections are minimal, researchers noted, especially once you move away from the tip of the catheter. 

Charles E. Mullins, MD, a U.S. Army veteran who went on to practice medicine for five decades, died at the age of 92. SCAI shared a loving tribute to Mullins, calling him the "father of modern interventional pediatric cardiology."

E-cigarettes, or vapes, are largely considered a safer alternative to smoking tobacco cigarettes, but new MRI data suggest they still pose significant risk to users’ health. 

Cardiothoracic surgeons at Emory University Hospital implanted the BrioVAD System, a new type of ventricular assist device from BrioHealth Solutions, for the very first time in the United States. The advanced technology, designed to minimize adverse events and improve quality of life, has been under development since 2008. 

The Sapien 3 Ultra Resilia TAVR valve from Edwards Lifesciences is associated with a significantly higher survival rate after one year than the company's previous balloon-expandable valves. Researchers identified other key benefits as well, sharing their findings in JACC: Cardiovascular Interventions.

Acoramidis, a selective transthyretin stabilizer being sold under the brand name Attruby, is now the second ATTR-CM medication to gain FDA approval.